Cambridge Cognition appoints Eric Dodd to Board as Non-Executive Director

– UK – Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, announces the appointment of Eric Dodd as a Non-Executive Director of the Company with immediate effect.

Eric Dodd, aged 44, brings significant experience in board-level positions to the Company, including having been Chief Financial Officer of Antisoma plc between 2008 and 2011. Currently, Mr Dodd acts as Chief Financial Officer of Stanmore Implants Worldwide Holdings Limited, a rapidly growing medical devices company supported by venture capital investors, where he is responsible for the finance, funding, corporate development and investor relations activities of the business. Previously Mr Dodd held positions in three FTSE 100 companies across the pharmaceutical, leisure and IT sectors. Mr Dodd will serve as Chair of the Company’s Remuneration Committee. Information in respect of Mr Dodd as required by Schedule 2(g) of the AIM Rules for Companies are included below.

Jane Worlock, Chairman of Cambridge Cognition, said: “Eric brings significant corporate and financial experience and knowledge, including within public companies, to the board of Cambridge Cognition, and we are pleased that we have been able to attract an individual of his calibre to the Company. We welcome him to the team.”

Eric Dodd, Non-Executive Director of Cambridge Cognition, said: “I am delighted to be joining Cambridge Cognition at this exciting stage of its development.”

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products.  The company’s range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-review publications, are used by both academic  scientists  in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function.  In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the CANTABmobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing.  Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care – leading to better outcomes for patients and their families.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.